rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AMRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Amneal Pharmaceuticals stock hits 52-week high at 22.07 USD
      10h agoInvesting.comAMRX
      Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing (NASDAQ:AMRX)
      Nov 17Seeking AlphaAMRX
      Amneal Pharmaceuticals stock hits 52-week high at $21.74
      Nov 11Investing.comAMRX
      AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
      Nov 4Yahoo FinanceAMRX
      Should Raised 2026 Guidance Require Action From Amneal Pharmaceuticals (AMRX) Investors?

      Amneal Pharmaceuticals reported past third quarter 2026 sales of US$862.68 million with adjusted EPS ahead of analyst estimates, while management lifted full year 2026 net revenue guidance to a range of US$3.15 billion to US$3.25 billion. The latest update highlights stronger contributions from complex generics, specialty brands and biosimilars, alongside reduced asset impairment charges compared with the prior year period. We will examine how Amneal Pharmaceuticals' higher 2026 revenue...

      Nov 4Yahoo FinanceAMRX
      Piper Sandler reiterates Amneal stock rating on earnings beat
      Nov 4Investing.comAMRX
      Amneal Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceAMRX
      What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
      Nov 3Yahoo FinanceAMRX
      Amneal Q3 2026 slides: seventh year of growth accelerates
      Nov 3Investing.comAMRX
      Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 3BenzingaAMRX
      Amneal Pharmaceuticals Raises 2026 Guidance After Q3 Revenue Climbs 10% to $862.7 Million
      Nov 3Yahoo FinanceAMRX
      Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 3Yahoo FinanceAMRX
      Amneal Pharmaceuticals earnings beat by $0.03, revenue topped estimates
      Nov 3Investing.comAMRX
      Amneal beats Q3 estimates, raises full-year guidance
      Nov 3Investing.comAMRX
      Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations
      Nov 3Yahoo FinanceAMRX
      Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates

      Amneal (AMRX) delivered earnings and revenue surprises of +8.33% and +5.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 3Yahoo FinanceAMRX
      Amneal (AMRX) Q3 earnings: what to expect
      Nov 3Yahoo FinanceAMRX
      Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability

      (StatePoint) Biological drug products (biologics) -- which can be made of sugars, proteins, living cells, tissues, or a

      Nov 2USA TodayAMRX
      Amneal earnings on deck: Can biosimilars offset margin pressure?
      Nov 2Investing.comAMRX
      Where Does Amneal Pharmaceuticals (AMRX) Value Sit After A 4.4x Run?
      Oct 29Yahoo FinanceAMRX
      Amneal Pharmaceuticals stock hits 52-week high at $21.18
      Oct 27Investing.comAMRX
      Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
      Oct 27Yahoo FinanceAMRX
      Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
      Oct 27Yahoo FinanceAMRX
      Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
      Oct 26Yahoo FinanceAMRX
      Amneal Pharmaceuticals (AMRX) Faces A Valuation Test Following Slowing Growth Concerns
      Oct 24Yahoo FinanceAMRX
      Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches

      The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...

      Oct 3Yahoo FinanceAMRX
      UBS reiterates Amneal Pharmaceuticals stock Buy rating on HRT growth
      Oct 1Investing.comAMRX
      Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says
      Sep 23Yahoo FinanceAMRX
      Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating
      Sep 23Investing.comAMRX
      Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target

      Amneal Pharmaceuticals (AMRX) has an average rating of buy and mean price target of $22, according t

      Sep 23Yahoo FinanceAMRX
      Amneal: Even My Bull Case Barely Justifies $20/Share (NASDAQ:AMRX)
      Sep 22Seeking AlphaAMRX
      Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Amneal Pharmaceuticals (AMRX)

      Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailAMRX
      Why Is Amneal (AMRX) Stock Rocketing Higher Today
      Sep 22Yahoo FinanceAMRX
      Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection
      Sep 21Yahoo FinanceAMRX
      Why Is Amneal (AMRX) Stock Rocketing Higher Today

      Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

      Sep 21The Globe and MailAMRX
      Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD
      Sep 21Investing.comAMRX
      AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod

      The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

      Sep 18Yahoo FinanceAMRX
      Amneal Pharmaceuticals Secures FDA Approval for Lanreotide Injection

      Amneal Pharmaceuticals (AMRX) said Friday that the US Food and Drug Administration approved its lanr

      Sep 18Yahoo FinanceAMRX
      Amneal receives FDA approval for generic lanreotide injection
      Sep 18Investing.comAMRX
      Amneal Announces FDA Approval and Launch of Lanreotide Injection

      - Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch imme

      Sep 18Yahoo FinanceAMRX
      Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

      Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

      Sep 17Yahoo FinanceAMRX
      Insider Unloading: KEVIN BUCHI Sells Options, Realizes $54K
      Sep 15BenzingaAMRX
      Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target
      Sep 9Yahoo FinanceAMRX
      Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?

      In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...

      Sep 5Yahoo FinanceAMRX
      Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats

      On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]

      Sep 4Yahoo FinanceAMRX
      Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism
      Sep 4Yahoo FinanceAMRX
      Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
      Sep 3Yahoo FinanceAMRX
      Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
      Aug 31BarchartAMRX
      Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Amneal Pharmaceuticals (AMRX) and Climb Bio (CLYM)

      Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

      Aug 27The Globe and MailJAZZAMRX

      This is the newest page. Registered accounts read further back.